SUMMARY OF THE ACTION AND SETTLEMENT

The information contained on this website is only a summary of the information presented in more detail in the Notice of (I) Proposed Class Action Settlement; (II) Settlement Hearing; and (III) Motion for Attorneys’ Fees and Litigation Expenses ("Settlement Notice"). Because this website is just a summary, you should review the Settlement Notice and Frequently Asked Questions ("FAQ"s) for additional details.

This website relates to a proposed Settlement of claims in a pending securities class action brought by investors alleging that Celgene Corporation ("Celgene") and certain of its officers, Terrie Curran and Philippe Martin (collectively, “Defendants”), violated the federal securities laws by making false and misleading statements during the Class Period (defined below) regarding certain Celgene products and product candidates, including the pharmaceutical drugs and drug candidates known as GED-0301, Otezla and Ozanimod.

Please be advised that the Class Representative AMF Tjänstepension AB (“Class Representative” or “Lead Plaintiff”), on behalf of itself and the Class (defined below), has reached a proposed Settlement of the Action for $239,000,000 in cash ("Settlement Fund"), plus interest as it accrues, minus attorneys' fees, costs, administrative expenses and any taxes on interest, to pay the claims of investors who purchased Celgene common stock during the Class Period and were damaged thereby.

If you are a member of the Class, you are subject to the Settlement. The Class was certified by the Court's Order dated November 25, 2020 and consists of:

All persons and entities who purchased the common stock of Celgene between April 27, 2017 and April 27, 2018, inclusive (“Class Period”), and were damaged thereby.

Excluded from the Class are: (i) Defendants; (ii) any directors and officers of Celgene during the Class Period and members of their Immediate Families; (iii) the subsidiaries, parents and affiliates of Celgene; (iv) any firm, trust, corporation or other entity in which Celgene has or had a controlling interest; and (v) the legal representatives, heirs, successors and assigns of any such excluded party.

Also excluded from the Class are: (i) all persons and entities who previously requested exclusion from the Class in connection with the mailing of the Class Notice; and (ii) Judge Michael E. Farbiarz, his current or former chambers staff, and any of his family members.

If you are a Class Member and you wish to be eligible to participate in the distribution of proceeds from the Settlement, you are required to submit a Claim Form and the required supporting documentation as set forth therein postmarked (or submitted online) no later than April 13, 2026. The Claim Form is available (in English and en español) on the File a Claim page of this website.

Payments to eligible claimants will be made after the Court approves the Settlement and the completion of all claims processing. Please be patient, as this process will take some time to complete.

How do I obtain more information?

Detailed information about the Action and the Settlement is contained in the Settlement Notice. Additional information can also be obtained by contacting the Claims Administrator by calling toll-free 1-855-648-0893; or emailing info@CelgeneSecuritiesLitigation.com; or mailing a letter to:

Celgene Corporation Securities Litigation
c/o JND Legal Administration
P.O. Box 91422
Seattle, WA 98111

Inquiries should NOT be directed to the Court or the Clerk of the Court.